Compare CENT & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CENT | GPCR |
|---|---|---|
| Founded | 1955 | 2016 |
| Country | United States | United States |
| Employees | 6000 | N/A |
| Industry | Consumer Specialties | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | N/A | 2023 |
| Metric | CENT | GPCR |
|---|---|---|
| Price | $39.01 | $39.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $50.00 | ★ $103.17 |
| AVG Volume (30 Days) | 41.9K | ★ 761.8K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.60 | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.77 | $15.80 |
| 52 Week High | $41.53 | $94.90 |
| Indicator | CENT | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 55.48 | 41.94 |
| Support Level | $35.18 | $30.82 |
| Resistance Level | $39.85 | $40.29 |
| Average True Range (ATR) | 1.04 | 2.11 |
| MACD | 0.08 | 0.42 |
| Stochastic Oscillator | 49.16 | 41.33 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.